Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion

Journal of Surgical Oncology

Volumn 104, Issue 4, 2011, Pages 397-404

  Testori, Alessandro ^a   Verhoef, Cornelis ^b   Kroon, Hidde M ^c   Pennacchioli, E ^a   Faries, Mark B ^d   Eggermont, Alexander M M ^e   Thompson, John F ^f,g  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RIJNLAND HOSPITAL   (Netherlands)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f MELANOMA INSTITUTE AUSTRALIA   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

isolated limb infusion; isolated limb perfusion; melanoma in transit metastases

Indexed keywords

CORTICOSTEROID; DACTINOMYCIN; DOXORUBICIN; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CATHETERIZATION; COMPARTMENT SYNDROME; DRUG EFFICACY; DRUG UPTAKE; EDEMA; ERYTHEMA; HEPARINIZATION; HUMAN; HYPERTHERMIA; INFUSION; ISOLATED LIMB INFUSION; ISOLATED LIMB PERFUSION; LIMB; LIMB PERFUSION; LYMPH NODE DISSECTION; MELANOMA; METASTASIS; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; MELANOMA; MELPHALAN; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051974503     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22028     Document Type: Review

References (69)

1. Creech O Jr, Krementz ET, Ryan RF, et al.: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-632.
2. Klaase JM, Kroon BB, van Geel AN, et al.: Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993; 80: 1124-1126. (Pubitemid 23284036)
3. Benckhuijsen C, Kroon BB, van Geel AN, et al.: Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157-163.
4. Thompson JF, Gianoutsos MP:, Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227-233.
5. Wieberdink J, Benckhuysen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910. (Pubitemid 13147887)
6. Omlor G:, Optimization of isolated hyperthermic limb perfusion. World J Surg 1993; 17: 134.
7. Cavaliere R, Ciocatto EC, Giovanella BC, et al.: Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20: 1351-1381.
8. Clark J, Grabs AJ, Parsons PG, et al.: Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994; 4: 365-370. (Pubitemid 24381889)
9. Di Filippo F, Anza M, Rossi CR, et al.: The application of hyperthermia in regional chemotherapy. Semin Surg Oncol 1998; 14: 215-223. (Pubitemid 28146513)
10. Vrouenraets BC, Klaase JM, Kroon BB, et al.: Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995; 130: 43-47.
11. Klaase JM, Kroon BB, van Geel AN, et al.: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115: 39-45. (Pubitemid 24039210)
12. Aloia TA, Grubbs E, Onaitis M, et al.: Predictors of outcome after hyperthermic isolated limb perfusion: Role of tumor response. Arch Surg 2005; 140: 1115-1120. (Pubitemid 41668683)
13. Klaase JM, Kroon BB, van Geel AN, et al.: A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71: 2990-2994. (Pubitemid 23145528)
14. Koops HS, Vaglini M, Suciu S, et al.: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906-2912.
15. Hafstrom L, Rudenstam CM, Blomquist E, et al.: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9: 2091-2094.
16. Lienard D, Ewalenko P, Delmotte JJ, et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
17. Eggermont AMM, de Wilt JHW, ten Hagen TLM:, Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 429-437. (Pubitemid 36833685)
18. de Wilt JH, ten Hagen TL, de Boeck G, et al.: Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000-1003. (Pubitemid 30128849)
19. van der Veen AH, de Wilt JH, Eggermont AM, et al.: TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000; 82: 973-980. (Pubitemid 30085254)
20. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004; 139: 1237-1242. (Pubitemid 39463461)
21. Alexander HR Jr, Fraker DL, Bartlett DL, et al.: Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010; 28: 114-118.
22. Lejeune FJ, Lienard D, Leyvraz S, et al.: Regional therapy of melanoma. Eur J Cancer 1993; 29A: 606-612. (Pubitemid 23036318)
23. Lienard D, Eggermont AM, Koops HS, et al.: Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502. (Pubitemid 29494115)
24. Rossi CR, Foletto M, Mocellin S, et al.: Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004; 11: 173-177. (Pubitemid 40486792)
25. Grunhagen DJ, Brunstein F, Graveland WJ, et al.: One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004; 240: 939-947.
26. Hayes AJ, Neuhaus SJ, Clark MA, et al.: Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007; 14: 230-238. (Pubitemid 44954294)
27. Di Filippo F, Giacomini P, Rossi CR, et al.: Prognostic factors influencing tumor response, loco-regional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. In Vivo 2009; 23: 347-352.
28. Lasithiotakis K, Economou G, Gogas H, et al.: Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: Feasibility and reproducibility in a multi-institutional Hellenic collaborative study. Oncol Rep 2010; 23: 1077-1083.
29. Fraker DL, Alexander HR, Andrich M, et al.: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14: 479-489.
30. Vrouenraets BC, Nieweg OE, Kroon BB:, Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 1996; 83: 1319-1322.
31. Eggermont AM, Schraffordt Koops H, Lienard D, et al.: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 1996; 14: 2653-2665. (Pubitemid 26329649)
32. Eggermont AM, Schraffordt Koops H, Klausner JM, et al.: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-764.
33. Cornett WR, McCall LM, Petersen RP, et al.: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196-4201. (Pubitemid 46622299)
34. Lejeune FJ, Eggermont AM:, Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 2007; 25: 1449-1450; author reply 1450-1451. (Pubitemid 46706902)
35. Rossi CR, Pasquali S, Mocellin S, et al.: Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. Ann Surg Oncol 2010; 17: 3000-3007.
36. Grunhagen DJ, de Wilt JH, van Geel AN, et al.: TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 2005; 31: 1011-1019. (Pubitemid 41671116)
37. Stam TC, Swaak AJ, de Vries MR, et al.: Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000; 7: 268-275. (Pubitemid 30318314)
38. van Etten B, van Geel AN, de Wilt JH, et al.: Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003; 10: 32-37.
39. Vrouenraets BC, Eggermont AM, Hart AA, et al.: Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001; 27: 390-395. (Pubitemid 32624542)
40. Francken AB, Accortt NA, Shaw HM, et al.: Prognosis and determinants of outcome following loco-regional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2008; 15: 1476-1484.
41. Thompson JF, Waugh RC, Saw RPM, et al.: Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Reg Cancer Treat 1994; 7: 188-192.
42. Kroon HM, Moncrieff M, Kam PC, et al.: Outcomes of isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008; 15: 3003-3013.
43. Thompson JF, Hunt JA, Shannon KF, et al.: Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903-907. (Pubitemid 27344144)
44. Roberts MS, Wu ZY, Siebert GA, et al.: Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001; 11: 423-431. (Pubitemid 32735234)
45. Karakousis CP, Kanter PM, Park HC, et al.: Tourniquet infusion versus hyperthermic perfusion. Cancer 1982; 49: 850-858. (Pubitemid 12184082)
46. Kroon HM, Thompson JF, Hoekstra HJ:, Isolated limb infusion for melanoma and sarcoma. A good alternative for isolated limb perfusion with cytotoxic drugs. Ned Tijdschr Geneesk 2009; 153: 508-514.
47. Moncrieff MD, Kroon HM, Kam PC, et al.: Outcomes of the use of isolated limb infusion for soft tissue sarcoma of the extremity. Ann Surg Oncol 2008; 15: 2749-2756.
48. Grünhagen DJ, Brunstein F, Graveland WJ, et al.: One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004; 240: 939-947.
49. Beasley GM, Caudle A, Petersen RP, et al.: A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 2009; 208: 706-715.
50. Mian R, Henderson MA, Speakman D, et al.: Isolated limb infusion for melanoma: A simple alternative to isolated limb perfusion. Can J Surg 2001; 44: 189-192. (Pubitemid 32538770)
51. Hegazy MA, Kotb SZ, Sakr H, et al.: Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007; 14: 568-576. (Pubitemid 46175302)
52. Ryan ER, Hill AD, Skehan SJ:, FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma. Clin Nucl Med 2006; 31: 707-708. (Pubitemid 44624560)
53. Beasley GM, Petersen RP, Yoo J, et al.: Isolated limb infusion for in-transit malignant melanoma of the extremity: A well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008; 15: 2195-2205.
54. Lindnér P, Doubrovsky A, Kam PCA, et al.: Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9: 127-136. (Pubitemid 34259697)
55. Barbour AP, Thomas J, Suffolk J, et al.: Isolated limb infusion for malignant melanoma: Predictors of response and outcome. Ann Surg Oncol 2009; 16: 3463-3472.
56. Brady MS, Brown K, Patel A, et al.: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13: 1123-1129. (Pubitemid 44337972)
57. Huismans AM, Kroon HM, Kam PCA, et al.: Does increased experience with isolated limb infusion for advanced melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol 2011; 18: 1877-1883.
58. Lindner P, Thompson JF, De Wilt JH, et al.: Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 2004; 30: 433-439. (Pubitemid 38528929)
59. Kroon HM, Moncrieff M, Kam PC, et al.: Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients. Ann Surg Oncol 2009; 16: 1184-1192.
60. Beasley IBW, McMahon N, Cheng TY, et al.: Optimizing melphalan pharmacokinetics in regional melanoma therapy: Does correcting for ideal body weight alter regional response or toxicity ? Ann Surg Oncol 2009; 16: 953-961.
61. Kroon HM, Lin DY, Kam PC, et al.: Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced loco-regional melanoma. Ann Surg 2009; 246: 1008-1013.
62. Kroon HM, Lin DY, Kam PC, et al.: Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol 2009; 16: 1193-1201.
63. Kroon HM, Lin DY, Kam PC, et al.: Efficacy of repeat isolated limb infusion with melphalan and actinomycin-D for recurrent melanoma. Cancer 2009; 115: 1932-1940.
64. Siemann DW, Chapman M, Beikirch A:, Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991; 20: 287-289.
65. Beasley GM, Ross MI, Tyler DS:, Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia 2008; 24: 301-309. (Pubitemid 351517162)
66. Beasley GM, McMahon N, Sanders G, et al.: A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 2009; 115: 4766-4774.
67. Lingam MK, Byrne DS, Aitchison T, MacKie RM, McKay AJ:, A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996; 32A: 1668-1673.
68. Bryant PJ, Balderson GA, Mead P, Egerton WS:, Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995; 19: 363-368.
69. Marsden J, Samarasinghe V, Duddy M, et al.: Regional chemotherapy for inoperable limb cancer using isolated limb infusion. Br J Dermatol 2008; 159 (S1): 10.